Evidence map›Paper›PMID 41875236›Full record

ArticleBlood advances2026

Cystic fibrosis and sickle cell disease associated with nonadministration of VTE prophylaxis in hospitalized adults.

Kiera Caparon, Matthew J Lankiewicz, Jessica Crow, Jennifer C Yui, John Lindsley, Brandyn D Lau, Michael B Streiff, Rakhi P Naik, Sophie Lanzkron, Lydia H Pecker and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kiera CaparonDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Matthew J LankiewiczDepartment of Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Jessica CrowDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Jennifer C YuiDepartment of Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD.
John LindsleyDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Brandyn D LauDepartment of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Michael B StreiffDepartment of Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Rakhi P NaikDepartment of Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Sophie LanzkronDivision of Medicine, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, PA.
Lydia H PeckerDepartment of Hematology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Peggy KrausDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Elliott R HautDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.ORCID 0000-0001-7075-771X
Jiangxia WangDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.ORCID 0000-0002-1715-3981
Kathryn E DaneDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractCystic fibrosis (CF) and sickle cell disease (SCD) are associated with an increased risk of venous thromboembolism (VTE), and this risk is exacerbated by hospitalization. VTE prophylaxis nonadministration is a VTE risk factor. The objective of this study was to characterize VTE prophylaxis nonadministration among patients with either CF or SCD compared with medically ill patients without CF or SCD. We conducted a single-center retrospective cohort study of hospitalized patients who were prescribed at least 2 doses of pharmacologic VTE prophylaxis. The primary outcome was the proportion of nonadministered VTE prophylaxis doses by cohort. Multivariable logistic regression was used to identify characteristics associated with nonadministration. A total of 13 316 patients were included, comprising 89 with CF, 246 with SCD, and 12 981 otherwise medically ill. During the study period, 95 697 doses were prescribed; nonadministration rates were 61.8% in the CF cohort, 32.7% in the SCD cohort, and 19.7% in the medically ill cohort (P< .01). In the multivariable logistic regression, CF or SCD diagnosis (odds ratio [OR], 2.03; 95% confidence interval [CI], 1.59-2.6), multiple admissions (OR, 2.4; 95% CI, 2.19-2.64), and >5 prescribed doses of VTE prophylaxis (OR, 2.48; 95% CI, 2.29-2.69) were associated with nonadministration of ≥1 dose. The percent of missed doses (median interquartile range [IQR]) per patient was highest in the CF cohort (66.7% [84.5]), followed by the SCD cohort (10.6% [50]), and medically ill cohort (0% [16.7]; P< .01). These findings suggest strategies to improve VTE prophylaxis administration rates during acute hospitalization in high-risk conditions such as CF and SCD are needed.

Indexed as

Anemia, Sickle CellCystic FibrosisVenous ThromboembolismAdultAnticoagulantsFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesRisk FactorsAnticoagulants

Identifiers

PMID41875236
PMCPMC13251665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.